Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions.
Beumer JH, Kennard BC, Holleran JL, Moore N, Zlott J, Miller BM, Kummar S, Chen A, Doroshow J, Park W, Gobburu J, Dunn A. Beumer JH, et al. Among authors: doroshow j. Cancer Chemother Pharmacol. 2023 Mar;91(3):219-230. doi: 10.1007/s00280-023-04509-8. Epub 2023 Feb 23. Cancer Chemother Pharmacol. 2023. PMID: 36813886 Free PMC article.
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Chen AP, et al. Among authors: doroshow jh. N Engl J Med. 2023 Sep 7;389(10):911-921. doi: 10.1056/NEJMoa2303383. N Engl J Med. 2023. PMID: 37672694 Free PMC article. Clinical Trial.
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Mittra A, Coyne GHOS, Zlott J, Kummar S, Meehan R, Rubinstein L, Juwara L, Wilsker D, Ji J, Miller B, Navas T, Ferry-Galow KV, Voth AR, Chang TC, Jiwani S, Parchment RE, Doroshow JH, Chen AP. Mittra A, et al. Among authors: doroshow jh. Cancer Chemother Pharmacol. 2024 Mar;93(3):177-189. doi: 10.1007/s00280-023-04600-0. Epub 2023 Nov 27. Cancer Chemother Pharmacol. 2024. PMID: 38010394 Free PMC article. Clinical Trial.
The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. O'Dwyer PJ, et al. Among authors: doroshow jh. Nat Med. 2023 Jun;29(6):1349-1357. doi: 10.1038/s41591-023-02379-4. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322121 Review.
Expanding access to early phase trials: the CATCH-UP.2020 experience.
Baranda JC, Diaz FJ, Rubinstein L, Shields AF, Dayyani F, Mehta A, Mehnert JM, Trent J, Mabaera R, Mooney M, Moscow JA, Doroshow J, Waters B, Ivy P, Gore SD, Thomas A. Baranda JC, et al. Among authors: doroshow j. JNCI Cancer Spectr. 2023 Jan 3;7(1):pkac087. doi: 10.1093/jncics/pkac087. JNCI Cancer Spectr. 2023. PMID: 36525371 Free PMC article.
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Meric-Bernstam F, et al. Among authors: doroshow jh. Mol Cancer Ther. 2024 Apr 20. doi: 10.1158/1535-7163.MCT-23-0471. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38641411
496 results